Adaptimmune Therapeutics (ADAP) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts ADAP Hot Sheet
Join SI Premium – FREE
Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $40.9 million versus the consensus estimate of $18.57 million.
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX signs compute deal with Reflection - CNBC
- Rockwell Automation launches FactoryTalk Orchestration software
- Reliance Global Group names new CTO, COO, and EVP for AI push
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
